Hematological Malignancies clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, accepting new patients by invitation only
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
San Francisco, California and other locations